General Information of Drug (ID: DM0TWCY)

Drug Name
PF-04950615 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hypercholesterolaemia 5C80.0 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DM0TWCY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9) TTBRG7E PCSK9_HUMAN Not Available [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hypercholesterolaemia
ICD Disease Classification 5C80.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proprotein convertase subtilisin/kexin type 9 (PCSK9) DTT PCSK9 4.82E-02 -0.07 -0.3
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01975376) The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects. U.S. National Institutes of Health.
2 Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8.